Randal S. Olshefski, MD

Dr. Olshefski is a member of the Section of Hematology/Oncology/ Blood and Marrow Transplant (BMT) at Nationwide Children’s Hospital and a Professor of Pediatrics at The Ohio State University College of Medicine. His clinical interest is the treatment of children and adolescents with primary benign and malignant brain tumors. His clinical research activities focus on clinical trials for treatment of brain tumors in children. Dr. Olshefski also has an interest in the treatment of patients with Langerhans cell histiocytosis (LCH). He is the institutional investigator for several international clinical trials in the treatment of LCH.

Gender:

• Male

Languages Spoken:

• English

Medical School

• University of Pittsburgh School of Medicine
  Date Completed: 05/23/1988

Internship

• Nationwide Children's Hospital
  Date Completed: 06/30/1989

Residency

• Nationwide Children's Hospital
  Date Completed: 06/30/1991

Fellowship

• Children's National Medical Center
  Date Completed: 06/30/1994

Fellowship

• Children's National Medical Center
  Date Completed: 06/30/1995

Department:

• Pediatrics

Section:

• Hematology/Oncology

Speciality:

• Pediatric Hematology Oncology
  

Date of Appointment at Nationwide Children’s Hospital:

• 01/22/1998

• Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius BAdolescent Aprepitant in Cancer Study Group (Adamson PC, Bagatell R, Boklan J, Drachtman RA, Hamre MR, Holdsworth MT, Little M, Olshefski R, Petrilli A, Weinstein JL). 2009. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.  Pediatr Blood Cancer.. Vol. 52, no. 2. (January): 242-247.
• Termuhlen AM, Klopfenstein K, Olshefski R, Rosselet R, Yeager ND, Soni S, Gross TG. 2008. Mobilization of PML-RARA negative blood stem cells and salvage with autologous peripheral blood stem cell transplantation in children with relapsed acute promyelocytic leukemia.  Pediatr Blood Cancer.. Vol. 51, no. 4. (October): 521-524.
• Fangusao J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitch M, Olshefski R, Halpern S, Dubowy R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller D, Allen J, S Gardner. 2008. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience.  Pediatr Blood Cancer. Vol. 50, no. January: 312-318.
• Altura RA, Olshefski RS, Jiang Y, and BR Bou´e. 2003. Nuclear expression of Survivin in pediatric ependymomas and choroids plexus tumors correlates with morphologic tumor grade.  British J. Cancer. Vol. 89, no. January: 1743-1749.
• Binkovitz L, Olshefski R, and B Adler. 2003. Coincidence FDG-PET in the evaluation of Langerhans’ cell histiocytosis: preliminary findings.  Pediatr Radiol. Vol. 33, no. January: 598-602.
• Olshefski R and S. Ladisch. 2001. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity.  Int. J. Cancer. Vol. 93, no. January: 131-138.
• Blanchong C, Olshefski R, and S. Kahwash. 2001. Large granular lymphocyte leukemia: Case report of chronic neutropenia and rheumatoid arthritis-like symptoms in a child.  Pediatr Dev Pathol.. Vol. 3, no. January: 94-99.
• Robinson R, Nahata M, and R. Olshefski. 2000. Syncope associated with concurrent amitripyline and fluconazole therapy.  Annals Pharmacother. Vol. 34, no. January: 1406-1408.
• Olshefski, R and S. Ladisch:. 1998. Synthesis, shedding,and intercellular transfer of human medulloblastoma gangliosides: Abrogation by a new inhibitor of glucosylceramide synthase.  J. Neurochem. Vol. 70, no. January: 467-472.
• Olshefski R, Taylor B, Heitger A, Hasagawa A, Ladisch S:. 1996. Induction of programmed cell death and immunosuppression by sphingolipids are separate processes.  Eur. J. Biochem. Vol. 241, no. January: 47-55.
• Olshefski R and Ladisch S:. 1996. Intercellular transfer of shed tumor gangliosides.  FEBS Lett. Vol. 386, no. January: 11-14.
• Ivy SP, Olshefski R, Taylor B, Patel K, and Reaman G. 1996. Correlation of P-glycoprotein expression and function in childhood acute leukemia.  Blood. Vol. 88, no. January: 309-318.
• Hrushesky WJM, Berestka JS, von Roemeling R, Olshefski R, Langevin TR, Potish RA, Delaney JP, Ellefson M, Schwartz S:. 1988. Methylene blue protects intestinal mucosa from free radical-mediated sublethal radiation damage.  Free Radical Biology and Medicine. Vol. 5, no. January: 207-213.
• Skubitz KM, Wick MR, Skubitz AP, Langevin TR, Olshefski RS, von Roemeling R, Southern RB, Hrushesky WJM:. 1986. Timing of Amphotericin B therapy is a critical determinant of toxicity. In: Reinberg A, Smolensky M, Labrecque G (eds).  Annual Review of Chronopharmacology, New York: Pergamon Press,. Vol. 3, no. January: 183-186.
• Von Roemeling R, Olshefski R, Lagevin T, Berestka J, Reusch JJ, Reusch JE, Lakatua D, Wick MR, Hrushesky WJM:. 1986. Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: Animal findings and preliminary clinical experiences.  Chronobiology International,. Vol. 3, no. January: 55-64.
• Hrushesky WJM, Olshefski R, Wood P, Eaton J, Meshnik S:. 1985. Modifying intracellular redox balance: An approach to improving therapeutic index.  Lancet,.